IFCT-GFPC 05.02 A Randomized Phase III Trial Assessing in Patients With Advanced Non-small Cell Lung Cancer
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
The objective of this trial is to improve the duration of control disease for PS 0-1 patients
who are not progressing on first-line cisplatin-gemcitabine chemotherapy. Standard therapy is
for these patients to stop first-line chemotherapy after 4 to 6 cycles and to begin a
second-line chemotherapy when progression of disease is occurring. Two approaches will be
experimented in this trial in attempt to prolong progression free survival :
- Maintenance chemotherapy with single-agent gemcitabine continued till disease
progression or toxicity.
- Sequential treatment with erlotinib immediately given after the end of first-line
chemotherapy.